Compile Data Set for Download or QSAR
Report error Found 130 Enz. Inhib. hit(s) with all data for entry = 12483
TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699247BDBM699247(US20240327430, Example 87 | US12145945, Example 87)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699248BDBM699248(US20240327430, Example 88 | US12145945, Example 88)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699245BDBM699245(US20240327430, Example 85 | US12145945, Example 85)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699246BDBM699246(US20240327430, Example 86 | US12145945, Example 86)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699243BDBM699243(US20240327430, Example 83 | US12145945, Example 83)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699244BDBM699244(US20240327430, Example 84 | US12145945, Example 84)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699241BDBM699241(US20240327430, Example 81 | US12145945, Example 81)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699242BDBM699242(US20240327430, Example 82 | US12145945, Example 82)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 705457BDBM705457(2'-chloro-N-(5-{[(2R)-2- hydroxypropyl]amino}- [1,...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 705458BDBM705458(2'-chloro-N-(5-{[(2S)-2- hydroxypropyl]amino}- [1,...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 705455BDBM705455(2'-fluoro-5'-methoxy-6-methyl-N-[5-(morpholin-4-yl...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699254BDBM699254(US20240327430, Example 94 | US12145945, Example 94)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699251BDBM699251(US20240327430, Example 91 | US12145945, Example 91)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699252BDBM699252(US20240327430, Example 92 | US12145945, Example 92)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699249BDBM699249(US20240327430, Example 89 | US12145945, Example 89)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699250BDBM699250(US20240327430, Example 90 | US12145945, Example 90)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699231BDBM699231(US20240327430, Example 71 | US12145945, Example 71)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699232BDBM699232(US20240327430, Example 72 | US12145945, Example 72)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699229BDBM699229(US20240327430, Example 69 | US12145945, Example 69)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699230BDBM699230(US20240327430, Example 70 | US12145945, Example 70)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699227BDBM699227(US20240327430, Example 67 | US12145945, Example 67)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 705430BDBM705430(2'-chloro-N-[6-(4-hydroxypiperidin-1-yl)- [1,3]thi...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699225BDBM699225(US20240327430, Example 65 | US12145945, Example 65)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699226BDBM699226(US20240327430, Example 66 | US12145945, Example 66)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699239BDBM699239(US20240327430, Example 79 | US12145945, Example 79)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699240BDBM699240(US20240327430, Example 80 | US12145945, Example 80)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699237BDBM699237(US20240327430, Example 77 | US12145945, Example 77)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699238BDBM699238(US20240327430, Example 78 | US12145945, Example 78)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699235BDBM699235(US20240327430, Example 75 | US12145945, Example 75)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699236BDBM699236(US20240327430, Example 76 | US12145945, Example 76)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699233BDBM699233(US20240327430, Example 73 | US12145945, Example 73)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699234BDBM699234(US20240327430, Example 74 | US12145945, Example 74)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699279BDBM699279(5-[(2-{2'-chloro-5'-methoxy-6-methyl- [4,4'-bipyri...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 705482BDBM705482(2'-chloro-5'-methoxy-6-methyl-N-{5- [(2H-1,2,3,4-t...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 705479BDBM705479(2'-chloro-5'-methoxy-6-methyl-N-[5-(2- oxopiperidi...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699278BDBM699278(5-[(2-{2'-chloro-5'-methoxy-6-methyl- [4,4'-bipyri...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699275BDBM699275(6-[(dimethylcarbamoyl)methyl]-5'- methoxy-N- {[1,3...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699276BDBM699276(N-[5-(4-hydroxypiperidin-1-yl)- [1,3]thiazolo[5,4-...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699287BDBM699287(2'-chloro-5'-methoxy-6-methyl-N-[6- (morpholin-3-y...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699288BDBM699288(2'-chloro-5'-methoxy-N-[6-(3- methoxyazetidin-1-yl...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699285BDBM699285(2'-chloro-N-[7-(cyanomethoxy)- [1,3]thiazolo[5,4-d...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699286BDBM699286(N-[7-(carbamoylmethoxy)- [1,3]thiazolo[5,4-d]pyrim...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699282BDBM699282(2-[(2-{2'-chloro-5'-methoxy-6-methyl- [4,4'-bipyri...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699228BDBM699228(US20240327430, Example 68 | US12145945, Example 12...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699281BDBM699281(2'-chloro-N-(5-hydroxy-1,3- benzothiazol-2-yl)-5'-...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699283BDBM699283(2'-chloro-N-[5-(2-hydroxyethoxy)-1,3- benzothiazol...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699263BDBM699263(2'-chloro-N-{5-[(dimethylcarbamoyl) difluoromethox...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699264BDBM699264(2'-chloro-5'-methoxy-6-methyl-N-[5- (methylcarbamo...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699261BDBM699261(2'-chloro-N-{5- [difluoro(methylcarbamoyl) Methoxy...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 699262BDBM699262(N-(5-bromo-1,3-benzothiazol- 2-yl)-2'-chloro-5'-me...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

Displayed 1 to 50 (of 130 total ) | Next | Last >>
Jump to: